0001415889-24-014338.txt : 20240523
0001415889-24-014338.hdr.sgml : 20240523
20240523174522
ACCESSION NUMBER: 0001415889-24-014338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240523
FILED AS OF DATE: 20240523
DATE AS OF CHANGE: 20240523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Batycky Alka
CENTRAL INDEX KEY: 0001978041
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39971
FILM NUMBER: 24979964
MAIL ADDRESS:
STREET 1: C/O LANDOS BIOPHARMA, INC.
STREET 2: P.O. BOX 11239
CITY: BLACKSBURG
STATE: VA
ZIP: 24062
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Landos Biopharma, Inc.
CENTRAL INDEX KEY: 0001785345
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 815085535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 KRAFT DRIVE, SUITE 216
CITY: BLACKSBURG
STATE: VA
ZIP: 24060
BUSINESS PHONE: 540-818-2844
MAIL ADDRESS:
STREET 1: 1800 KRAFT DRIVE, SUITE 216
CITY: BLACKSBURG
STATE: VA
ZIP: 24060
4
1
form4-05232024_050511.xml
X0508
4
2024-05-23
1
0001785345
Landos Biopharma, Inc.
LABP
0001978041
Batycky Alka
C/O LANDOS BIOPHARMA, INC.
PO BOX 11239
BLACKSBURG
VA
24062
true
false
false
false
0
Stock Option (right to buy)
3.05
2024-05-23
4
D
0
3600
D
Common Stock
3600
0
D
Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.
/s/ Eric W. Blanchard, Attorney-in-Fact
2024-05-23